Everyone at Leadiant Biosciences works with rare dedication to provide therapies for patients with rare diseases. We partner with patient communities, physicians and researchers worldwide to overcome challenges and be a resource of hope.


Leadiant Biosciences Ltd. is the European arm of Leadiant Biosciences S.p.A. Formerly known as Sigma-Tau Rare Disease, Leadiant Biosciences is a research-based global pharmaceutical company that dedicates considerable resources to the development, registration and commercialization of novel and effective therapies that address patient needs and improve quality of life.

Founded in Italy in 1957, we take pride in seeing value in medicines that others miss and strive to bring novel therapies to market that transform the lives of those affected by disease.

Our experienced, passionate team is committed to delivering treatments to patients who need them. As a private company, we focus first and foremost on serving patients while also providing a meaningful return to our shareholders. We continually reinvest in research to develop the next generation of pharmaceuticals to meet the needs of patients with specific diseases.

Leadiant Biosciences, Inc. is the North American arm of Leadiant Biosciences S.p.A. (Corporate).